CCM
MOLN

CAAS Capital Management’s Molecular Partners MOLN Stock Holding History

CAAS Capital Management’s Portfolio MOLN Stock Details MOLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-23,071
Closed -$452K – 978
2021
Q3 		$452K Sell
23,071
-36,929
-62% -$726K 0.01% 643
2021
Q2 		$1.23M Buy
+60,000
New +$1.19M 0.02% 502

Other funds holding MOLN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

CAAS Capital Management's MOLN Position: Q4 2021 in Review

CAAS Capital Management sold out of Molecular Partners (MOLN) in Q4 2021, closing a stake of 23,071 shares — an estimated $452K sold.

CAAS Capital Management first reported a position in MOLN in Q2 2021 and held it in 2 quarters. The position peaked at $1.23M in Q2 2021. 9 funds tracked by Wall St. Rank hold MOLN as of Q4 2021.

  • CAAS Capital Management reported no remaining Molecular Partners position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 23,071 Molecular Partners shares in Q4 2021, an estimated $452K.
  • CAAS Capital Management first reported a position in Molecular Partners in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Molecular Partners position peaked at $1.23M in Q2 2021.
  • 9 funds tracked by Wall St. Rank held Molecular Partners as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.